0000883984-26-000029
SEC filingICU Medical delivered a profitable Q1 FY2026 with net income of $30.1M — a sharp reversal from a $15.5M loss a year earlier — supported by disciplined cost management and improved operating leverage, even as revenue declined 12.3% to $530.2M.
Revenue for Q1 FY2026 was $530.2M, down 12.3% from $604.7M in Q1 FY2025. This decline reflects fluctuations in net sales tied to variations in the ordering patterns of ICU Medical’s largest customers — patterns driven more by production scheduling and customer inventory levels than by seasonal demand. The company notes that such variability is inherent to its business model and does not indicate a structural shift in underlying demand.
Gross profit was $206.2M, a modest 1.8% decrease year-over-year, yet gross margin improved to 38.9%. Management attributes this expansion to three supported factors: implementation of price increases, lower supply chain costs, and realization of integration synergies. These drivers collectively enhanced profitability per unit sold, even amid lower overall volume.
Operating income increased 5.4% to $13.6M, resulting in an operating margin of 2.6%. This growth occurred despite revenue contraction, underscoring the effectiveness of ongoing cost discipline and operational streamlining. The improvement reflects sustained focus on overhead management and absorption of fixed costs across a refined product portfolio.
Net income was $30.1M, reversing from a $15.5M net loss in Q1 FY2025 — a 294.7% year-over-year improvement. Diluted EPS was $1.20, compared to $(0.63) in the prior year. This inflection point signals a meaningful step toward consistent profitability, supported by both operational execution and structural improvements in the cost base.
Net cash provided by operating activities was $38.9M, compared to $51.3M in Q1 FY2025. Capital expenditures were $11.3M, down from $14.6M, resulting in free cash flow of $27.6M. Inventory decreased due to lower production volumes at certain sites, influenced by material shortages from suppliers and delays related to plant transfers — operational realities acknowledged in management commentary. Accrued liabilities declined primarily due to the timing of annual bonus payouts, partially offset by higher deferred revenue.
Management reaffirms its ability to fund capital expenditures and contractual obligations using existing cash and cash equivalents, along with cash generated from future operations. External uncertainties — including geopolitical developments such as the conflict in Iran — may continue to affect commodity price volatility and regional operating conditions, though no material near-term impact has been reported.